Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in NAFLD
NCT05308160Phase 3Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-alcoholic fatty liver disease (NAFLD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Safety Outcome Measure at 6 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05308160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308160.